Skip to main content
Premium Trial:

Request an Annual Quote

VisEn, Merck to Co-Develop Fluorescence Agents for Biomarker Imaging

NEW YORK (GenomeWeb News) — VisEn Medical and Merck & Co. plan to develop and apply fluorescence agents to image disease-related biomarkers in vivo, VisEn said today.
 
Merck aims to integrate the companies’ technologies to develop drug candidates and to “establish new standards for the identification and assessment of disease,” said Richard Hargreaves, Merck’s vice president of imaging.
 
VisEn said the program will use proprietary and literature-derived biomarkers linked to cardiovascular disease together with VisEn’s fluorescence agents and fluorescence molecular tomography imaging systems.
 
The agents will be used in in vivo imaging tools to track how diseases progress and show a therapeutic response.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.